AKT1 and obesity disorder: Considering the key role of cAMP and PI3K/Akt pathways in cardio-renal diseases, obesity, and T2DM, GLP-1 RA could be a potential pharmacological tool in a wide range of patients, including those with cancer and associated cardiovascular diseases [24,25].